EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 16

Kava Piper methysticum

Also called: kava kava, awa, ava pepper, ava root, kawa

Kava (Piper methysticum) is an Oceanian shrub; its root and rhizome are used for traditional water-based drinks and kavalactone extracts, studied mostly for anxiety. Kava products have been linked to rare, sometimes serious liver injury; reviews name plant material, preparation, raw-material quality and dose as possible factors.

Category
Botanical
Part used
Root and rhizome (rootstock)
Strongest evidence
B Some positive trials
Reviewed
2026-10-30

Class 1 Well studied in people. A 2003 Cochrane review included 12 double-blind RCTs (700 participants) of oral kava extract mono-preparations versus placebo for anxiety; 7 were pooled in a meta-analysis. [3]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

2 topics studied1 body area · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Kava does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Kava, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Anxiety symptomsBCochrane 2003: 12 RCTs (700 participants); pooling 7 (380 participants), Hamilton Anxiety scores fell 3.9 points more than placebo (95% CI 0.1 to 7.7); the authors said the effect lacks robustness and rests on a relatively small sample. [3]
Generalized anxiety disorderXA 16-week phase III RCT in 171 adults with diagnosed GAD found no significant difference from placebo; remission was 17.4% with kava versus 23.8% with placebo. [4]

Main constituents: Kavalactones (kavapyrones) [2]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Aqueous extract of dried kava root standardized to 120 mg of kavalactones twice/day for 16 weeks (GAD trial). [4]
  • LiverTox cites a suggested dose for nonpsychotic anxiety of 105 to 210 mg daily for three to four weeks. [2]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Score A
    A: well known causeE: unlikely cause

    LiverTox likelihood score A (well known cause of clinically apparent liver injury), chapter last updated April 10, 2018.

    Details and sources
  • Pregnancy and breastfeeding
    NCCIH: kava may carry special risks in pregnancy and breastfeeding because of harmful pyrone constituents.

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    4 listed

    Benzodiazepines, alcohol and other sedating substances; Alprazolam; CYP enzymes; Drugs that can affect the liver

    Details and sources
  • Cancer evaluations (IARC, NTP)
    4 found

    Each names the exact material tested, which may differ from a supplement.

    Details and sources
  • FDA new dietary ingredient notifications
    2 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • LiverTox likelihood score A (well known cause of clinically apparent liver injury): hepatocellular injury, with symptoms typically 2 to 24 weeks after starting; severity ranges from transient and moderate enzyme elevations to symptomatic acute hepatitis to acute liver failure, and fulminant cases may require liver transplant. Rechallenge leads to prompt recurrence. [2]
  • LiverTox: based on reported cases, the estimated frequency of clinically apparent liver injury due to kava is less than 1:1,000,000 daily doses. The cause is unclear; clinical cases suggest an idiosyncratic or immunoallergic mechanism, and in vitro studies suggest kavalactones are not intrinsically cytotoxic, although other components of kava preparations may be. [2]
  • A 2002 CDC report described 11 kava users who needed liver transplants (2 in the US, 9 in Europe). [6]
  • WHO (2007) reviewed 93 case reports (7 deaths, 14 liver transplants); most were incomplete, 8 were coded 'probable', 53 'possible' and most others unassessable. It concluded that kava lactones in any type of product may rarely cause liver reactions, and that products made from acetonic and ethanolic extracts appear hepatotoxic on rare occasions, seemingly from non-kavalactone constituents. Its literature review noted that clinical trials had not revealed hepatotoxicity. [7]
  • WHO (2007) named as apparent risk factors organic extracts, heavy alcohol intake, pre-existing liver disease, genetic polymorphisms of cytochrome P450 enzymes and excessive dose; co-medication with potentially hepatotoxic or interacting drugs might also lead to harm. It suggested the higher rate with organic extracts could be due to incorrect plant parts or inappropriate cultivars, and recommended that kava not be used by people with liver disease or a history of it, or who take excessive alcohol. [7]
  • WHO (2007) stated that water extracts as taken in the South Pacific, with hardly any serious kava-related hepatotoxicity reported, are chemically different from the kava used to make pills in Europe, and that this difference could be responsible for the reported hepatotoxicity in some kava pill takers. [7]
  • NCCIH: the first reported cases involved products extracted with alcohol or acetone, but other cases have involved kava beverages prepared with water. Suggested contributors include undesirable cultivars, inappropriate plant parts, alcohol, adulteration or contamination, genetic differences and large or prolonged consumption. [1]
  • A 2010 clinical review applying a liver-specific causality method to 14 patients rated causality for kava (with or without co-medicated drugs or supplements) highly probable (1), probable (4) or possible (9), involving aqueous (3), ethanolic (5) and acetonic (4) extracts and kava mixtures (2). The author concluded injury occurred independently of solvent, with overdose, prolonged use, co-medication and probably poor raw-material quality as factors (review's interpretation). [8]
  • A 2012 review concluded that cases analyzed by WHO and published case reports show traditional aqueous extracts may also be hepatotoxic, so the earlier idea that toxicity was limited to Western acetonic and ethanolic extracts is no longer supported; it suggested poor raw-material quality, possibly from mold hepatotoxins, as a primary cause (review's hypothesis). [15]
  • In an Arnhem Land (Australia) cross-sectional study of 98 people, recent use of aqueous kava (average 118 g of powder per week) was associated with higher GGT and ALP but not ALT or bilirubin; the changes appeared reversible, beginning to return to baseline after 1 to 2 weeks without kava. [13]
  • Among 31 regular drinkers of traditionally prepared kava beverages in Hawaii (predominantly Tongan), GGT was elevated in 65% versus 26% of 31 non-drinkers (P = .005). [14]
  • Flavokavain B: a 2010 laboratory study reported that this chalcone from kava root killed human liver cells in culture (HepG2 LD50 15.3 µM; in vitro) and that oral dosing caused severe liver damage in an in vivo animal experiment; the authors said its levels should be monitored and controlled in kava products. [10]
  • A 2011 review reported abundant in vitro cytotoxicity data for pipermethystine and flavokavain B but said evidence was lacking of liver toxicity in experimental animals under conditions similar to human kava use; in commercial Western extracts pipermethystine was not detectable and flavokavain B was present in amounts much too low to cause experimental liver injury (review's conclusion). [9]
  • In the 16-week GAD trial, liver function test abnormalities were significantly more frequent with kava; no participant met criteria for herb-induced liver injury. Poorer memory and tremor were also more frequent. [4]
  • Cochrane 2003: data from the reviewed trials suggest kava is relatively safe for short-term treatment (1 to 24 weeks), although more information is required; long-term safety studies are needed. [3]
  • Long-term high-dose use may cause kava dermopathy (dry, scaly skin, reddened eyes, temporary yellowing of skin, hair and nails). Other effects: digestive upset, headache, dizziness. [1]
  • Pregnancy and breastfeeding: kava may carry special risks because of harmful pyrone constituents. [1]
Interactions

Interactions

Kava
From the table below 4 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Kava
WithWhat happens
Benzodiazepines, alcohol and other sedating substancesAvoid combining kava with other sedating substances. [1]
Antipsychotics, other anxiolytics and antithromboticsWHO (2007) found that kava products have a strong propensity for kava-drug interactions and recommended warnings that kava not be used with these drugs because of the risk of interactions, which could include effects on the liver. [7]
Drugs that can affect the liverPeople taking such drugs, or with liver disease, should consult a physician before using kava-containing supplements (FDA, 2002). [5]
CYP enzymesIn vitro studies suggest kavalactones inhibit several CYP enzymes; human studies suggest kava inhibits CYP2E1 alone, with modest effects. [2]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • LiverTox: the possibility of mislabeling or adulteration with hepatotoxic herbals is always an issue. [2]
  • WHO (2007): raw materials came from a variety of sources without adequate quality control or sufficient standardization of plant varieties, cultivars or plant parts. Stem peelings contain compounds not present in the roots, and studies show use of aerial parts is potentially dangerous. Closely related species (Piper wichmannii, P. aduncum, P. auritum) have reportedly been marketed as kava. [7]
  • WHO (2007) recommended a pharmacopoeial standard; use of only the root or rhizome of Piper methysticum, with no other species and no aerial parts; agreement on appropriate cultivars; standardized quality control for growing, harvesting and processing; and clinical testing of water-based and synthetic products, considered in preference to acetonic and ethanolic extracts. [7]
  • In 172 samples from four cultivar groups, the flavokavin B to kavalactone ratio was much higher in 'two-days' (0.39) and wichmannii (0.32) than in noble (0.09) and medicinal (0.10) cultivars, did not change significantly between roots, stumps or basal stems, and appears genetically controlled; the authors describe an HPTLC screen that could be used for quality control (Lebot et al., 2014). [11]
  • A 2011 review found little evidence that kavalactones, pipermethystine or flavokavain B cause the liver reactions and concluded that poor quality of the kava material appears responsible; it proposed an international kava quality standardization code (review's conclusion). [12]
Regulation

Regulatory status

  • US: sold as a dietary supplement ingredient; dietary supplements are not approved by the FDA before sale, and manufacturers are responsible for safety and labeling. [1]
  • US: on March 25, 2002, the FDA issued a consumer advisory that kava-containing dietary supplements may be associated with severe liver injury. [5]
  • Germany, Switzerland, Canada, Australia and France restricted the sale of kava-containing products because of liver adverse events (CDC, 2002). [6]
  • LiverTox (2018) states that kava has been banned or restricted in many countries, such as Germany, Switzerland, France, Canada and Great Britain, and that kava in many formulations remains available from nutrition stores and the internet; its annotated references include a review of the 2014 German court reversal of the 2002 regulatory ban. [2]
  • Australia and New Zealand (Food Standards Code Standard 2.6.3, compilation in force March 23, 2022): the food prohibition on kava does not apply to dried or raw kava root, or to a beverage made by aqueous suspension of kava root using cold water only and no organic solvent. 'Kava root' means the peeled root or peeled rootstock of a Noble variety named in Codex regional standard CXS 336R-2020. Required warnings: 'Use in moderation' and 'May cause drowsiness'. [16]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Kavalactones (kavapyrones), named by LiverTox as the active ingredients Kavalactones (kavapyrones) [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 2 entries naming kava (earliest NDI 1050 submitted 2017-11-15; most recent NDI 1134 submitted 2019-11-22). Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P2]
  • On March 25, 2002, FDA issued a consumer advisory that kava-containing dietary supplements may be associated with severe liver injury. [P3]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • IARC: kava extract is classified in Group 2B (possibly carcinogenic to humans), IARC Monographs Volume 108 (2016). [P4]
  • IARC basis for Group 2B (Monographs Vol. 108, kava chapter): inadequate evidence in humans for the carcinogenicity of kava extract (the Working Group identified only one epidemiological study, an ecological study it considered uninformative) and sufficient evidence in experimental animals, from one gavage study in mice and one in rats. IARC judged the reported carcinogenicity in mice most likely to be mediated through a nongenotoxic mechanism. [P9]
  • NTP TR-571 (2012), kava kava extract by gavage for 2 years: clear evidence of carcinogenic activity in male B6C3F1 mice (hepatoblastoma); some evidence in female mice (hepatocellular adenoma or carcinoma combined); equivocal evidence in male F344/N rats (testicular interstitial cell adenoma); no evidence in female rats. [P5]
  • NTP TR-571 test material and doses: a kava kava root extract (medium-yellow powder) given in corn oil; the six major kavalactones totaled 26.99% of the batch used in the 2-year studies. Rats received 0, 0.1, 0.3 or 1.0 g/kg and mice 0, 0.25, 0.5 or 1.0 g/kg, 5 days per week for 104 or 105 weeks. The 3-month and 2-year studies were conducted under FDA Good Laboratory Practice regulations (21 CFR Part 58). [P10]
  • NTP noted species differences: liver toxicity occurred in both rats and mice, but liver tumors only in mice, which appear more sensitive than rats to liver-tumor induction. Its genetic toxicology results and published data suggest the extract is not mutagenic, and the mouse carcinogenic activity is most likely mediated through nongenotoxic mechanisms. At peer review, asked how the doses compared with typical human exposure, the NIEHS scientist presenting the study said toxicity and carcinogenicity studies typically use doses several times the normal human dosage and that there is very little information about human exposure to herbal products. [P10]

Liver (NIH LiverTox)

  • LiverTox likelihood score A (well known cause of clinically apparent liver injury), chapter last updated April 10, 2018. [P1]
  • LiverTox: based on reported cases, the estimated frequency of clinically apparent liver injury due to kava is less than 1:1,000,000 daily doses; the cause is unclear, and clinical cases suggest an idiosyncratic or immunoallergic mechanism. [P1]
  • WHO (2007) reviewed 93 case reports (7 deaths, 14 liver transplants; 8 coded 'probable', 53 'possible', most others unassessable). It concluded kava lactones in any type of product may rarely cause liver reactions, and that acetonic and ethanolic extract products appear hepatotoxic on rare occasions, seemingly from non-kavalactone constituents. [P11]

Interactions with medicines

  • Benzodiazepines, alcohol and other sedating substances: NCCIH advises avoiding combining kava with other sedating substances. [P6]
  • Alprazolam: LiverTox annotates a case report titled 'Coma from the health food store: interaction between kava and alprazolam'. [P1]
  • CYP enzymes: Human studies suggest kava is an inhibitor of CYP2E1 alone, and that its effects are modest (about 40% inhibition in an annotated volunteer study). [P1]
  • Drugs that can affect the liver: FDA (2002) advised people taking such drugs, or with liver disease, to consult a physician before using kava-containing supplements. [P3]

Alcohol

  • NCCIH lists alcohol use among possible contributors to kava liver injury and advises avoiding combining kava with alcohol and other sedating substances. [P6]
  • In a human study, kava alone had little effect on reported condition and cognitive performance but appeared to potentiate both perceived and measured impairment when combined with alcohol (Foo and Lemon, 1997). [P7]
  • WHO (2007) named heavy alcohol intake among apparent risk factors for kava liver reactions and recommended that kava not be used by people who take excessive alcohol. [P11]

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • LiverTox: the possibility of mislabeling or adulteration with hepatotoxic herbals is always an issue; an annotated review suggests aflatoxin contamination may be the cause of rare instances of liver injury. [P1]
  • NCCIH lists undesirable cultivars, inappropriate plant parts and adulteration among possible contributors to liver injury. [P6]
  • WHO (2007): stem peelings contain compounds not present in the roots, and use of aerial parts is potentially dangerous; closely related species (Piper wichmannii, P. aduncum, P. auritum) have reportedly been marketed as kava in some South Pacific islands. [P11]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of each dietary-ingredient component — 21 CFR 111.75(a)(1)(i) requires at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, unless FDA grants an exemption petition under 111.75(a)(1)(ii). [P8]
  • Plant-part identity (root) and cultivar documentation — Undesirable cultivars and inappropriate plant parts are listed by NCCIH as possible contributors to kava liver injury. [P6]
  • Aflatoxins — An annotated review in LiverTox suggests aflatoxin contamination may explain rare instances of kava liver injury. [P1]
  • Cultivar chemotype screen (flavokavin B to kavalactone ratio, e.g. by HPTLC) — In 172 samples, the flavokavin B to kavalactone ratio was much higher in 'two-days' (0.39) and wichmannii (0.32) cultivars than in noble (0.09) and medicinal (0.10) cultivars; the authors describe the HPTLC screen as usable for quality control. [P12]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • NCCIH: kava may carry special risks in pregnancy and breastfeeding because of harmful pyrone constituents. [P6]

Sources for this profile

  1. NIH LiverTox. Kava Kava (last update April 10, 2018), 2018-04-10. ncbi.nlm.nih.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. US FDA/CFSAN. Kava-containing dietary supplements may be associated with severe liver injury (consumer advisory, March 25, 2002; archived), 2002-03-25. webarchive.library.unt.edu
  4. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1-142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  5. National Toxicology Program. TR-571: Toxicology and Carcinogenesis Studies of Kava Kava Extract in F344/N Rats and B6C3F1 Mice (Gavage Studies) (2012), abstract, 2012-03. ntp.niehs.nih.gov
  6. NCCIH. Kava (Last Updated: April 2025), 2025-04. nccih.nih.gov
  7. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev 1997;16(2):147-155 (PMID 16203421), 1997-06. pubmed.ncbi.nlm.nih.gov
  8. eCFR. 21 CFR 111.75 What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  9. IARC. Kava. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 108: Some Drugs and Herbal Products (Lyon, 2016), 2016. publications.iarc.who.int
  10. National Toxicology Program. TR-571: Toxicology and Carcinogenesis Studies of Kava Kava Extract in F344/N Rats and B6C3F1 Mice (Gavage Studies) (2012), full technical report, 2012-03. ntp.niehs.nih.gov
  11. World Health Organization. Assessment of the risk of hepatotoxicity with kava products (WHO, Geneva, 2007), 2007. iris.who.int
  12. Lebot V, Do TK, Legendre L. Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC). Food Chem 2014;151:554-560 (PMID 24423570), 2014-05-15. pubmed.ncbi.nlm.nih.gov
Sources

Sources

  1. NCCIH. Kava (Last Updated: April 2025), 2025-04. nccih.nih.gov
  2. NIH LiverTox. Kava Kava (last update April 10, 2018), 2018-04-10. ncbi.nlm.nih.gov
  3. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev 2003, Issue 1 (CD003383), 2003-01-20. cochrane.org
  4. Sarris J, et al. Kava for generalised anxiety disorder: a 16-week double-blind, randomised, placebo-controlled study. Aust N Z J Psychiatry 2020;54(3):288-297, 2020-03. pubmed.ncbi.nlm.nih.gov
  5. US FDA/CFSAN. Kava-containing dietary supplements may be associated with severe liver injury (consumer advisory, March 25, 2002; archived), 2002-03-25. webarchive.library.unt.edu
  6. CDC. Hepatic toxicity possibly associated with kava-containing products: United States, Germany, and Switzerland, 1999–2002. MMWR 2002;51(47):1065, 2002-11-29. cdc.gov
  7. World Health Organization. Assessment of the risk of hepatotoxicity with kava products (WHO, Geneva, 2007), 2007. iris.who.int
  8. Teschke R. Kava hepatotoxicity: a clinical review. Ann Hepatol 2010;9(3):251-265 (PMID 20720265), 2010-07. pubmed.ncbi.nlm.nih.gov
  9. Teschke R, Qiu SX, Lebot V. Herbal hepatotoxicity by kava: update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Dig Liver Dis 2011;43(9):676-681 (PMID 21377431), 2011-09. pubmed.ncbi.nlm.nih.gov
  10. Zhou P, et al. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. FASEB J 2010;24(12):4722-4732 (PMID 20696856), 2010-12. pubmed.ncbi.nlm.nih.gov
  11. Lebot V, Do TK, Legendre L. Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC). Food Chem 2014;151:554-560 (PMID 24423570), 2014-05-15. pubmed.ncbi.nlm.nih.gov
  12. Teschke R, Lebot V. Proposal for a kava quality standardization code. Food Chem Toxicol 2011;49(10):2503-2516 (PMID 21756963), 2011-10. pubmed.ncbi.nlm.nih.gov
  13. Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol 2003;41(6):821-829 (PMID 14677792), 2003. pubmed.ncbi.nlm.nih.gov
  14. Brown AC, et al. Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii. Clin Toxicol (Phila) 2007;45(5):549-556 (PMID 17503265), 2007-06. pubmed.ncbi.nlm.nih.gov
  15. Teschke R, Sarris J, Schweitzer I. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited. Br J Clin Pharmacol 2012;73(2):170-174 (PMID 21801196), 2012-02. pubmed.ncbi.nlm.nih.gov
  16. Australian Government Federal Register of Legislation. Australia New Zealand Food Standards Code, Standard 2.6.3 Kava (Compilation No. 3, in force March 23, 2022), 2022-03-23. legislation.gov.au
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.